Indicadores do estado corporal do ferro e indicadores de inflamação durante o tratamento da doença inflamatória intestinal em crianças e adolescentes / Body iron status indicators and inflammation indicators during inflammatory bowel disease therapy in children and adolescentes

ABSTRACT BACKGROUND: The treatment of patients with inflammatory bowel disease (IBD) consists of the induction and maintenance remission of the disease. Iron status indicators would be useful for the diagnosis of iron deficiency anemia, whereas the inflammation indicators would be for the diagnosis of chronic disease anemia. OBJECTIVE: To assess body iron status indicators and inflammation indicators during the treatment of IBD, consisted of conventional or infliximab therapy in children and adolescents. METHODS: A case-control study of a sample of 116 individuals, of which 81 patients with IBD, 18 of them receiving conventional therapy, 20 infliximab therapy, and 43 who were in remission of the disease, and 35 healthy (control group) children and adolescents. Iron status and inflammation indicators were investigated at baseline, and 2 and 6 months of both therapies - conventional and infliximab. RESULTS: The mean age was 12.1±4.3 years. At baseline, both groups - conventional therapy and infliximab - presented significant differences in most markers studied compared to the control group. After 2 months of conventional therapy, hemoglobin and serum iron levels were lower than those of the control group; and red cells distribution width (RDW), total iron-binding capacity, transferrin receptor/ferritin ratio, and interleukin-6 were higher than the control group. After 2 months of infliximab treatment, hemoglobin and serum iron levels were lower than those of the control group; and RDW, soluble transferrin receptor, soluble transferrin receptor/ferritin ratio, and interleukin-6 were higher than the control group. After 6 months of conventional therapy, hemoglobin and serum iron levels were lower than those of the control group, and RDW and interleukin-6 were higher than those of the control group. After 6 months of infliximab treatment, the hemoglobin and serum iron levels were lower than the control group, and RDW, soluble transferrin receptor, soluble transferrin receptor/ferritin ratio, erythrocyte sedimentation rate, and platelets were higher than the control group. Regarding patients under treatment for at least one year (remission group), all markers studied, except transferrin, were similar to the control group. CONCLUSION: In conclusion, there were some contradictions among the different body iron status indicators and inflammation indicators at two and 6 months of treatment with conventional and infliximab therapy, however after one year of treatment, as shown by the remission group, all indicators studied, except transferrin, were similar to healthy children and adolescents.

RESUMO CONTEXTO: O tratamento de pacientes com doença inflamatória intestinal (DII) consiste na indução e manutenção da remissão da doença. Os indicadores do estado corporal do ferro seriam úteis para o diagnóstico da anemia por deficiência de ferro, enquanto os indicadores de inflamação para o diagnóstico da anemia da doença crônica. OBJETIVO: Avaliar os indicadores do estado corporal do ferro e os indicadores de inflamação durante o tratamento da doença inflamatória intestinal, com terapia convencional ou infliximabe em crianças e adolescentes. MÉTODOS: Estudo de caso-controle de uma amostra de 116 indivíduos, sendo 81 pacientes com DII, dos quais 18 com terapia convencional, 20 infliximabe e 43 em remissão da doença, e 35 crianças e adolescentes saudáveis (grupo controle). Os indicadores do estado do ferro e os indicadores de inflamação foram avaliados no início, 2 e 6 meses de dois tipos de tratamento - terapia convencional e terapia com infliximabe. RESULTADOS: A média de idade foi de 12,1±4,3 anos. No início do tratamento, ambos os grupos - terapia convencional e infliximabe - apresentaram diferenças significantes com relação à maioria dos marcadores estudados comparados ao grupo controle. Após 2 meses de terapia convencional, os níveis de hemoglobina e ferro sérico foram inferiores em comparação ao grupo controle; e amplitude de distribuição dos eritrócitos (RDW), capacidade total de ligação do ferro, razão entre o receptor de transferrina solúvel e ferritina e interleucina-6 foram superiores aos do grupo controle. Após 2 meses de tratamento com infliximabe os níveis de hemoglobina e ferro sérico foram inferiores em comparação ao grupo controle, e RDW, receptor de transferrina solúvel e interleucina-6 foram superiores aos do grupo controle. Após 6 meses de terapia convencional, os níveis de hemoglobina e ferro sérico foram inferiores aos do grupo controle, e RDW e interleucina-6 superiores aos do grupo controle. Após 6 meses de tratamento com infliximabe, os níveis de hemoglobina e ferro sérico foram inferiores comparados ao grupo controle, e RDW, receptor de transferrina solúvel, razão receptor de transferrina solúvel e ferritina, taxa de sedimentação de eritrócitos e plaquetas foram superiores ao do grupo controle. Quanto aos pacientes que estavam em tratamento há mais de um ano (grupo remissão), todos os marcadores, exceto a transferrina, foram similares ao grupo controle. CONCLUSÃO: Houve contradições entre os diferentes indicadores do estado corporal do ferro e dos indicadores de inflamação aos 2 e 6 meses de tratamento com terapia convencional e infliximabe, no entanto após um ano de tratamento, conforme observado pelo grupo em remissão, todos os indicadores estudados, exceto a transferrina, foram semelhantes aos das crianças e adolescentes saudáveis.

Assistência à saúde de pessoas com doenças colorretais no sistema público a perspectiva do usuário / Health care for people with colorectal diseases in the public system: the user's perspective

Trata-se de um estudo de desenho misto, do tipo sequencial explanatório, sendo que na etapa quantitativa descritiva e transversal, objetivou-se analisar a demanda de atendimento de assistência de pessoas com queixas colorretais em Unidades de Saúde da Família no Sistema Único de Saúde (SUS); e na etapa qualitativa exploratória, interpretar o mapa de cuidado de pessoas com adoecimento colorretal crônico no SUS (Parecer No. 210/2018 CEP/EERP-USP). Na etapa quantitativa aplicou-se um instrumento de coleta de dados, elaborado pelas pesquisadoras, com base na revisão de literatura, para caracterização sociodemográfica, clínica, terapêutica e de referência de participantes usuários da Estratégia Saúde da Família com queixas colorretais, mediante critérios de inclusão e exclusão, no período de abril a setembro de 2019. A análise estatística descritiva dos dados indicou, que do total de 107 participantes, predominou 78 (72,9%) que tinham idade acima de 60 anos, 64 (59,8%) eram do sexo feminino, 61 (57%) tinham até oito anos de estudos, 68 (63,65) com companheiro, 56 (52,3%) eram aposentados, 45 (42,1%) apresentavam renda de até um salário mínimo e 95 (88,8%) não possuíam plano de saúde privado, sendo que o encaminhamento para o nível secundário foi devido ao protocolo de rastreamento para 62 (57,9%) e 45 (42,1%) por queixa colorretal, todos haviam realizado a Pesquisa de Sangue Oculto e destes, 78% tiveram resultado positivo; todos os entrevistados haviam recebido encaminhamento para realizar a colonoscopia. Além disso, 78 (72,9%) eram sedentários; e 66 (61,7%) consumiam carne vermelha e 45 (42,1%) embutidos. A análise univariada da associação das variáveis hábitos de vida, resultado de colonoscopia, presença de alterações displásicas ou doença colorretal não foi estatisticamente significante entre consumo de carne vermelha, consumo de embutidos ou ambos com o desfecho de colonoscopia normal, displasia intestinal com potencial neoplásico e doença diverticular ou orificial. Estes resultados dimensionaram o contexto de atendimento desta clientela na Atenção Primária à Saúde (APS), auxiliando o refinamento dos critérios de seleção dos possíveis participantes da etapa qualitativa. A etapa qualitativa foi realizada, no período de junho de 2020 a julho de 2020, mediante os critérios de seleção: pessoas acima de 18 anos, de ambos os sexos, com diagnóstico colorretal crônico: Doença inflamatória intestinal ou Neoplasia colorretal em internação especialidade de Coloproctologia de um hospital universitário público, de assistência terciária/quaternária. Nesta etapa, os dados foram coletados por meio de entrevistas individuais em profundidade com 14 participantes, cuja caracterização sociodemográfica, clínica e terapêutica revelou internação para tratamento cirúrgico, com maior gravidade clínica, sendo que 13 apresentavam diagnóstico de Neoplasia colorretal. Utilizou-se questões norteadoras, diário de campo, observação não participante e participante para a obtenção dos dados, que foram interpretados com Análise Temática, fundamentado pela Epidemiologia Social. O Mapa de Cuidado construído por estes, iniciou-se com queixas e sinais/sintomas gastrointestinais, envolvendo situações de maior gravidade clínica, com sofrimento físico e psicoemocional; diagnosticados como parasitose, hemorroidas e anemia na APS, cujos tratamentos não foram resolutivos. Para esta interpretação, articulou-se as ações destes participantes às suas queixas, à condição socioeconômica, cultural e psicoemocional, assim como à capacidade de enfrentamento do adoecimento oncológico e dos tratamentos, no qual ocorreu a focalização da vida destes e de suas famílias nos acontecimentos clínicos e terapêuticos do contexto de atendimento terciário/quaternário. O acesso aos serviços do SUS ocorreu de diferentes maneiras, com utilização de estratégias que agilizaram e asseguraram a resolução do seu problema de saúde, sendo que o agir leigo foi uma produção social, no cotidiano do SUS, mediado pelos acontecimentos, pelas ações dos profissionais e de suas próprias ações ou pelo sistema de apoio social, enfatizando-se o sofrimento desta clientela na busca pela assistência à saúde. Este mapa de cuidado mostrou que o agir leigo constituiu uma regulação assistencial no SUS, tão importante quanto as outras formas, composto pelos vínculos dos pacientes com profissionais dos serviços dos níveis primário, secundário, terciário/quaternário, de suas necessidades e possibilidades, além dos pontos de acesso ao sistema. Estes resultados poderão contribuir na implementação da gestão de cuidados de pessoas com adoecimento colorretal crônico no SUS, dando voz e protagonismo àquele que busca pela assistência à saúde

This is a study of mixed design, of an explanatory sequential type, and in the quantitative descriptive and transversal stage, the objective was to analyze the demand for assistance from people with colorectal symptoms in Family Health Units in the Unified System Health (SUS); and in the qualitative exploratory stage, interpret the care map for people with chronic colorectal illness in SUS (Note Nº. 210/2018 CEP / EERP-USP). In the quantitative stage, a data collection instrument was developed by the researchers, based on the literature review, for sociodemographic, clinical, therapeutic, and reference characterization of participating users of the Family Health Strategy with colorectal symptoms, considering inclusion and exclusion criteria, from April to September 2019. The descriptive statistical analysis of the data indicated that, out of a total of 107 participants, 78 (72.9%) predominated who were over 60 years old, 64 (59.8%) were female, 61 (57%) had up to eight years of study, 68 (63.65) with a partner, 56 (52.3%) were retired, 45 (42.1%) had an income of up to one minimum wage and 95 (88.8%) did not have a private health plan, and the referral to the secondary level was due to the screening protocol for 62 (57.9%) and 45 (42.1%) due to colorectal complaints, all had carried out the Occult Blood Survey and of these, 78% had a positive result; all respondents had been referred for colonoscopy. In addition, 78 (72.9%) were sedentary; and 66 (61.7%) consumed red meat and 45 (42.1%) sausages. The univariate analysis of the association of the variables life habits, the result of colonoscopy, presence of dysplastic changes or colorectal disease was not statistically significant between consumption of red meat, consumption of sausages or both with the outcome of normal colonoscopy, intestinal dysplasia with neoplastic potential and diverticular or artificial disease. These results have dimensioned the context of care for this clientele in Primary Health Care (PHC), helping to refine the selection criteria of possible participants in the qualitative stage. The qualitative stage was carried out, from June 2020 to July 2020, using the selection criteria: people over 18 years of age, of both sexes, with chronic colorectal diagnosis: Inflammatory bowel disease or Colorectal neoplasia in Coloproctology specialty hospitalization of a public university hospital, of tertiary/quaternary assistance. In this stage, data were collected through in-depth individual interviews with 14 participants, whose sociodemographic, clinical, and therapeutic characterization revealed hospitalization for surgical treatment, with greater clinical severity, with 13 presenting a diagnosis of colorectal neoplasia. Guiding questions, field diary, non-participant and participant observation were used to obtain the data, which were interpreted with Thematic Analysis, based on Social Epidemiology. The Care Map built by them started with gastrointestinal complaints and signs/symptoms, involving situations of greater clinical severity, with physical and psycho-emotional suffering; diagnosed as parasitosis, hemorrhoids, and anemia in PHC, whose treatments were not effective. For this interpretation, the actions of these participants were linked to their complaints, to their socioeconomic, cultural, and psycho-emotional condition, as well as to their ability to cope with oncological illness and treatments, in which the lives of these and their families were focused on the events and therapeutic aspects of the tertiary/quaternary care context. Access to SUS services occurred in different ways, using strategies that streamlined and ensured the resolution of their health problem, and the lay agency as social production, in the daily routine of SUS, mediated by events, by the actions of professionals and their actions or the social support system, emphasizing the suffering of this clientele in the search for health care. This care map showed that the lay act constituted an assistance regulation in SUS, as important as the other forms, composed by the bonds of patients with professionals from the services of the primary, secondary, tertiary/quaternary levels, of their needs and possibilities, in addition to the access points to the system. These results may contribute to the implementation of the care management of people with chronic colorectal illness in SUS, giving voice and leadership to those seeking health care.

Mortalidad en enfermedad inflamatoria intestinal / Mortality in inflammatory bowel disease

Inflammatory bowel disease (IBD) is a chronic disease of unknown cause. It has been attributed to an inflammation of the intestinal mucosa due to loss of immunotolerance to commensal intestinal flora in genetically predisposed individuals. It presents short- and long-term complications, impacting the quality of life and increasing patient mortality, although this risk is slightly increased with respect to the general population. Causes of mortality may be due to complications of the disease, secondary to drugs or surgical complications. Mortality associated with the disease, it occurs mainly in the first 5 years of diagnosis, due to the increased risk of acute complications such as severe ulcerative colitis, toxic megacolon and massive digestive hemorrhage. In addition, patients with IBD are at increased risk of digestive tract and extraintestinal neoplasias. Colorectal cancer occurs as a consequence of chronic inflammation of the colonic mucosa. Extraintestinal neoplasms include lung cancer, hematologic malignancies such as lymphoma, cholangiocarcinoma, cervical cancer, and skin cancer. They also present an increased risk of cardiovascular and thromboembolic diseases, associated with the prothrombotic state of these patients. This review aims to describe the main causes of mortality in IBD patients, in order to be able to prevent the disease and provide opportune diagnosis

La enfermedad inflamatoria intestinal (EII) es una enfermedad crónica de causa desconocida. Su etiología se ha atribuido a una inflamación de la mucosa intestinal debido a una pérdida de la inmunotolerancia a la flora intestinal comensal en individuos genéticamente predispuestos. La EII puede presentar complicaciones a corto y largo plazo, lo que puede afectar la calidad de vida y mortalidad de los pacientes, siendo este riesgo levemente mayor con respecto a la población general. Las causas de mortalidad pueden ser consecuencia de las complicaciones propias de la enfermedad, secundaria a fármacos o por complicaciones quirúrgicas. En cuanto a la mortalidad asociada a la enfermedad, se presenta principalmente en los primeros 5 años de diagnóstico, por mayor riesgo de complicaciones agudas como colitis ulcerosa grave, megacolon tóxico y hemorragia digestiva masiva. Además, los pacientes con EII presentan mayor riesgo de neoplasias tanto del tubo digestivo como extraintestinales. El cáncer colorrectal se presenta como consecuencia de la inflamación crónica de la mucosa colónica. Dentro de las neoplasias extraintestinales se encuentran el cáncer de pulmón, neoplasias hematológicas como el linfoma, colangiocarcinoma, cáncer cervicouterino y cáncer de piel. También presentan mayor riesgo de enfermedades cardiovasculares y tromboembólicas, asociadas al estado protrombótico de estos pacientes. Esta revisión tiene como objetivo describir las principales causas de mortalidad en los pacientes con EII, con el fin de poder prevenirlas y diagnosticarlas oportunamente.

Terapias biológicas en enfermedad inflamatoria intestinal: puesta al día / Biologics therapies in inflammatory bowel disease: an update

Inflammatory bowel disease (IBD) is a chronic condition that significantly compromises the quality of life of patients. Biologicals have improved the course of the disease and its prognosis; however, not all patients have access to these treatments due to its high cost. Biosimilars seem to be a safe and effective option in the treatment of IBD. Because of its lower cost, the number of patients who have been treated increases every day. It is important to consider that not all patients respond to anti-TNF so alternatives have emerged within biological therapies that have demonstrated efficacy, and others are being tested. Antiintegrins emerge strongly as a new therapeutic model of IBD. With all these options probably the future treatment will be more personalized and less protocolized according to the characteristics of each patient.

La enfermedad inflamatoria intestinal (EII) es crónica y determina un notable compromiso de la calidad de vida de los pacientes que lo padecen. Los biológicos han mejorado el curso de la enfermedad y su pronóstico, sin embargo, no todos los pacientes tienen acceso a estos tratamientos debido a su alto costo. Los biosimilares parecen ser una opción segura y eficiente en el tratamiento de la EII. Debido a su menor costo cada día aumenta el número de pacientes que han sido tratados. Es importante considerar que no todos los pacientes responden a los anti TNF por lo que han surgido otras alternativas dentro de los biológicos que han demostrado eficacia y otros que se encuentran en evaluación. Los biológicos antiintegrinas surgen con fuerza como nuevo modelo terapéutico de las EII. Con todas estas alternativas es planteable que el tratamiento a futuro sea más personalizado y menos protocolizado según las características de cada paciente.

Desarrollo de neoplasia en pacientes con enfermedad inflamatoria intestinal / Development of malignant tumors in patients with inflammatory bowel disease

Background: The chronic inflammation of the intestinal mucosa, the extra-intestinal manifestations of the disease and the immunosuppressive treatment of inflammatory bowel disease may increase cancer risk. Aim: To report the demographic and clinical features of patients with IBD who developed a malignant tumor. Material and Methods: Retrospective analysis of an IBD patient registry of a private clinic, diagnosed between 1976 and 2014. Results: 437 subjects were included, aged 15-88 years (58% women). Seventy two percent of patients had ulcerative colitis. The median time of follow up was 6 years. Ten patients (2.3%) developed a malignant tumor. In four, the tumor could be related to IBD (two colorectal cancers, one cholangiocarcinoma and one chronic myeloid leukemia (CML)). Two of 45 patients treated with biological therapy developed a tumor (CML and hypernephroma). Three of 170 patients on immunosuppressive treatment developed tumors. Only one had a tumor possibly related with the use of azathioprine (non-melanoma skin cancer). In only two patients, the treatment was changed at the time of their cancer diagnosis, from immunosuppressive medications to mesalamine. Conclusions: Only a small proportion of these patients with IBD developed a malignant tumor. The treatment of IBD has to be determined by the severity of the disease and not by the fear of developing a neoplasia. Following recommendations is fundamental to decrease the possibility of developing this complication.

Adesão ao tratamento medicamentoso de pacientes com doenças inflamatórias intestinais acompanhados no ambulatório de um hospital universitário / Compliance to drug therapy in inflammatory bowel diseases outpatients from an university hospital

RACIONAL: A adesão ao tratamento medicamentoso nas doenças inflamatórias intestinais apresenta grande importância clínica e social. Porém, são escassos os estudos sobre este tema em nosso meio. OBJETIVO: Investigou-se a adesão ao tratamento medicamentoso prescrito, bem como a influência de alguns fatores sobre a adesão, de pacientes com doenças inflamatórias intestinais em acompanhamento em ambulatório de Gastroenterologia de um hospital universitário ligado ao Sistema Único de Saúde (SUS). MÉTODO: Realizou-se estudo transversal, com métodos indiretos, para avaliar a adesão ao tratamento de 26 casos da doença de Crohn, 26 pacientes com retocolite ulcerativa e 4 com colite indeterminada, que faziam uso contínuo de medicamentos, dos quais 89,3 por cento eram fornecidos pelo SUS. Os pacientes foram classificados como tendo alto ou baixo grau de adesão, com base em dois diferentes instrumentos. RESULTADOS: A análise dos medicamentos utilizados revelou baixa adesão em 15,4 por cento de pacientes com doença de Crohn e 13,3 por cento com retocolite ulcerativa. Porém, o teste de Morisky, que avalia hábitos de uso dos medicamentos, mostrou 50 por cento de baixa adesão na doença de Crohn e 63,3 por cento na retocolite ulcerativa. Análise univariada evidenciou na doença de Crohn relação entre baixa adesão e maior duração da doença, estado marital instável, residência próxima ao hospital e envolvimento do cólon. Na retocolite ulcerativa observou-se relação entre baixa adesão e atividade da doença e maior número de medicamentos em uso. Porém, a análise multivariada não evidenciou relação estatisticamente significativa que indicasse influência de qualquer fator sobre a adesão ao tratamento. CONCLUSÕES: Proporções elevadas de pacientes com doenças inflamatórias intestinais apresentam hábitos de uso de medicamentos indicativos de baixa adesão, difíceis de prever a partir de dados demográficos e clínicos, o que aponta para a necessidade de maior atenção...

BACKGROUND: Compliance to drug therapy is important for a successful treatment. Although many studies have assessed compliance to treatment in patients with chronic diseases, few investigations have been carried out in inflammatory bowel diseases. AIM: To assess compliance to drug therapy in patients with inflammatory bowel diseases - Crohn's disease and ulcerative colitis -, followed at a university hospital, who had prescribed medication supplied by the Brazilian National Health System. METHODS: In a cross sectional study, a structured interview was applied to assess the compliance of 26 Crohn's disease patients, 26 ulcerative colitis patients and 4 cases with undetermined colitis. Patients were characterized as presenting higher or lower degree of compliance, based on the comparison of the information provided by the patient in the interview and data in the medical records. The Morisky test was also used to assess the behavioral pattern of the patient regarding the daily use of the medication. RESULTS: The interview showed that 15.4 percent of patients with Crohn's disease and 13.3 percent of those with ulcerative colitis could be regarded as less compliant. However, the Morisky test revealed lower compliance in 50 percent of patients with Crohn's disease and 63.3 percent of those with ulcerative colitis. Univariate analysis showed an association between low compliance and long disease duration, married status and colon involvement in Crohn's disease, and between low compliance and increased disease activity and greater number of medications in ulcerative colitis. However, multivariate analysis did not confirm any association between low compliance and any demographic or clinical factor. CONCLUSIONS: A high degree of noncompliance to treatment, linked to habitual behavior and hard to predict from demographic or clinical factor, was detected in inflammatory bowel disease patients, which suggests the need for investment in patient education...

Enfermedades inflamatorias intestinales: experiencia de dos centros chilenos / Inflammatory bowel disease: experience of two chilean centers

Background: The incidence of Inflammatory Bowel Disease (IBD) has increased, particularly in the developed world, and probably also in Chile. Aim: To report our experience with a large group of patients from two medical centers, Hospital Clinico de la Universidad de Chile (HCUCH) and Clinica Las Condes (CLC) and to characterize the clinical features of IBD in Chile. Patients and methods: Retrospective review of 238 patients with IBD (age range 14-78 years, 143 women) treated at HCUCH and CLC between January 1990 and August 2002. Results: One hundred eighty one patients had ulcerative colitis (UC) and 57 had Crohn's disease (CD), with an UC/CD ratio of 3.2/1. Forty eight percent of patients were aged between 20 and 39 years old and 69% were diagnosed after 1995. Patients from HCUCH had more severe disease, more complications and needed surgery more often. Conclusions: Clinical features of Chilean patients with IBD are similar to those of other countries. UC is more common than EC. There is a higher proportion of women with the disease. The severity of the disease was higher among HCUCH.

El rol de los prebióticos, probióticos y simbióticos en gastroenterología / Role of prebiotics, probiotics and sinbiotics in gastroenterology

El tracto gastrointestinal es indudablemente el área más expuesta a microorganismos y antígenos dietarios. El epitelio intestinal es un importante componente de la barrera de la mucosa intestinal, el cual debe discriminar adecuadamente entre bacterias patogénicas y no-patogénicas. La flora bacteriana intestinal tiene un efecto condicionador sobre la homeostasis del intestino, entregando señales que regulan el epitelio, el sistema inmune de la mucosa y la actividad neuromuscular del intestino. Estudios han demostrado que la flora bacteriana comensal y sus componentes, son factores importantes en la patogénesis de varias enfermedades gastrointestinales, tales como la enfermedad inflamatoria intestinal, síndrome intestino irritable, cáncer de colon, enfermedad hepática crónica. Aunque estudios experimentales han demostrado que prebióticos, probióticos y simbióticos ejercen efectos antibacterianos, modulación inmune y antiinflamatorios, lo cual puede ser beneficioso en algunas enfermedades gastrointestinales, su real papel en el ser humano aún debe ser evaluado. Porque no todos poseen el mismo efecto terapéutico, colonización con específicos probióticos y simbióticos (incluyendo la ingeniería bacteriana para secretar citokinas anti-inflamatorias y restaurar la flora comensal y la tolerancia intestinal) podría ser la próxima estrategia para el tratamiento de las enfermedades gastrointestinales y otras enfermedades inmunológicas.

Profile of the inflammatory bowel disease patient with depressive disorders

OBJECTIVE: To describe the demographic and clinical characteristics of patients attending the Inflammatory Bowel Disease Clinic of the University of Puerto Rico School of Medicine and determine whether these characteristics are risk factors for the development of a depressive disorder. METHOD: Sixty-seven patients attending the Inflammatory Bowel Disease Clinic of the University of Puerto Rico School of Medicine were assessed for the presence of depressive symptoms using a simple questionnaire (CES-D) and a detailed diagnostic evaluation (CIDI-DSM IV Module E). Age, gender, education, time of IBD diagnosis, duration of treatment, psychiatric history, treatment with corticosteroids, and activity of IBD were determined and correlated with the presence of depressive symptoms and depressive diagnosis. Study data was tabulated on Epi-Info 6.0 and it was analyzed using SPSS version 10. Univariate (includes means and frequencies), bivariate (t-student, Kruskal Wallis and Chi-square) and multivariate analyses (logistic regression) were performed. RESULTS: Patients older than 34 years old had three times higher probability of developing a depressive disorder (p = 0.043, OR = 3.22). Patients with a psychiatric history had seven times higher probability of developing depressive disorder (p = 0.004, OR = 7). CONCLUSION: The risk factors identified with an increased probability of developing a depressive disorder were age older than 34 years and psychiatric history.